Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:32 PM
Ignite Modification Date:
2025-12-24 @ 10:32 PM
NCT ID:
NCT01661335
Eligibility Criteria:
Inclusion Criteria:
under 20.99 years of age at enrollment
Scheduled to receive two identical cycles of highly emetogenic\[1\] chemotherapy for treatment of a primary malignancy, including:
Chemotherapy with any one or more of the following single agents in any combination:
* Carboplatin
* Carmustine \>250 mg/m2
* Cisplatin
* Cyclophosphamide ≥1 g/m2
* Dactinomycin
* High dose Methotrexate ≥ 5 g/m2
Or any of the following defined combinations:
* Cyclophosphamide + anthracycline
* Cyclophosphamide + etoposide
* Cytarabine 150-200 mg/m2 + daunorubicin
* Cytarabine 300 mg/m2 + etoposide
* Cytarabine 300 mg/m2 + teniposide
* Doxorubicin + ifosfamide
* Doxorubicin + methotrexate 5 g/m2
* Etoposide + ifosfamide
Exclusion Criteria:
* Patients who have received aprepitant in the past.
* Patients who demonstrate evidence of increased intracranial pressure.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
6 Months
Maximum Age:
20 Years
Study:
NCT01661335
Study Brief:
Protocol Section:
NCT01661335